{"url_path":"/sec/ocgn/8-k/2026-05-14/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1372299/0001104659-26-061241-index.html","accession_number":"0001104659-26-061241","cik":"0001372299","ticker":"OCGN","issuer_name":"Ocugen, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1372299/0001104659-26-061241-index.html","primary_entity_key":"0001372299","primary_entity_name":"Ocugen, Inc."},"word_count":73,"has_tables":true,"body_markdown":"**Item 8.01. Other Events.**\n\n \n\nEffective May 8, 2026, the Company appointed Mohamed Genead, M.D.,\nM.Sc., as Acting/Interim Chief Medical Officer.\n\n \n\n2\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n \n**OCUGEN, INC.**\n\n \n \n \n\nDate: May 14, 2026\nBy:\n/s/ Shankar Musunuri\n\n \n \nName: Shankar Musunuri\n\n \n \nTitle: Chairman, Chief Executive Officer, & Co-Founder\n\n \n\n3"}